cagrisema cagrilintide semaglutide phase 3 obesity drug: what the data shows Novo Nordisk's CagriSema 2.4 mg

This was accompanied by improvements in menstrual frequency and ovulation markers, suggesting weight loss and the alleviation of central obesity are likely critical mediators of reproductive benefit (109)

Its time to lose weight and keep it off

Exercise-induced ultrastructural changes in skeletal muscle

The primary concern is cardiovascular stress: phentermine raises heart rate and blood pressure, while adding a GLP-1 receptor agonist can cause additional hemodynamic changes and increase the risk of arrhythmias or myocardial complications in susceptible individuals

Applying a cool compress after injection may also help reduce local inflammation

MITF upregulates tyrosinase, the rate-limiting enzyme that converts L-tyrosine to L-DOPA, the precursor to eumelanin and pheomelanin